BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

Efficacy of a Single Dose of Aspirin vs. Acetaminophen in Tension Type Headache

Phase 3

Terminated

Conditions: Headache

Interventions: Drug: Acetylsalicylic acid (Aspirin, BAY1019036)
Drug: Placebo
Drug: Acetaminophen

First Posted Date: 2012-03-13

Last Posted Date: 2018-12-19

Lead Sponsor: Bayer

Target Recruit Count: 9

Registration Number: NCT01552798

Locations: 🇺🇸
Westside Family Medical Center, Kalamazoo, Michigan, United States

Gadobutrol Pharmacokinetic and Safety Study in Pediatric Subjects Aged <2 Years (Term Newborn Infants to Toddlers 23 Months of Age Inclusive)

Phase 1

Completed

Conditions: Magnetic Resonance Imaging

Interventions: Drug: Gadobutrol (Gadavist, BAY86-4875)

First Posted Date: 2012-03-05

Last Posted Date: 2020-12-16

Lead Sponsor: Bayer

Target Recruit Count: 44

Registration Number: NCT01544166

Sorafenib in Hepatocellular Carcinoma Clinical Practice in Italy

Completed

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Sorafenib (Nexavar, BAY43-9006)

First Posted Date: 2012-02-27

Last Posted Date: 2016-02-18

Lead Sponsor: Bayer

Target Recruit Count: 234

Registration Number: NCT01539681

Study to Characterize Lung Deposition, Pharmacokinetics, Safety and Tolerability of Single Inhalations of Radiolabeled Ciprofloxacin Dry Powder in Healthy Subjects and Patients With Chronic Lung Diseases

Phase 1

Completed

Conditions: Respiratory System

Interventions: Drug: Ciprofloxacin (Cipro Inhale, BAYQ3939)

First Posted Date: 2012-02-24

Last Posted Date: 2014-08-21

Lead Sponsor: Bayer

Target Recruit Count: 24

Registration Number: NCT01538667

Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy

Conditions: Colorectal Neoplasms

First Posted Date: 2012-02-24

Last Posted Date: 2019-05-29

Lead Sponsor: Bayer

Registration Number: NCT01538680

Study to Observe Safety of Xarelto in VTE Prophlylaxis After Elective TKR (Total Knee Replacement) or THR (Total Hip Replacement)

Withdrawn

Conditions: Total Knee Replacement
Total Hip Replacement
Prophylaxis, Thromboembolism, Venous

Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939)

First Posted Date: 2012-02-01

Last Posted Date: 2016-02-04

Lead Sponsor: Bayer

Registration Number: NCT01523418

Controlled Release Nifedipine and Valsartan Combination Therapy in Patients With Essential Hypertension

Phase 4

Completed

Conditions: Hypertension

Interventions: Drug: Amlodipine (Norvasc)
Drug: Nifedipine (Adalat, BAYA1040)
Drug: Diovan

First Posted Date: 2012-01-26

Last Posted Date: 2012-01-26

Lead Sponsor: Bayer

Target Recruit Count: 514

Registration Number: NCT01518855

Open Study of BAY77-1931 (Lanthanum Carbonate) in Continuous Ambulatory Peritoneal Dialysis Patients

Phase 3

Completed

Conditions: Hyperphosphatemia

Interventions: Drug: Lanthanum Carbonate (BAY77-1931)

First Posted Date: 2012-01-26

Last Posted Date: 2016-03-14

Lead Sponsor: Bayer

Target Recruit Count: 43

Registration Number: NCT01518387

Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases

Conditions: Prostatic Neoplasms

First Posted Date: 2012-01-25

Last Posted Date: 2014-07-14

Lead Sponsor: Bayer

Registration Number: NCT01516762

Venous Thromboembolism (VTE) Treatment Study in Japanese Pulmonary Embolism (PE) Patients

Phase 3

Completed

Conditions: Pulmonary Embolism

Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939)
Drug: Warfarin
Drug: Unfractionated heparin

First Posted Date: 2012-01-25

Last Posted Date: 2017-01-23

Lead Sponsor: Bayer

Target Recruit Count: 40

Registration Number: NCT01516814

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy